SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for CytoDyn Inc. (CYDY) (CIK 0001175680) (CYDY) — Jul 14, 2014

CytoDyn Inc. (CYDY) (CIK 0001175680)
Date: July 14, 2014 · CIK: 0001175680 · Accession: 0000000000-14-035435

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
July 14, 2014
Author
/s/ Daniel Greenspan for
Form
UPLOAD
Company
CytoDyn Inc. (CYDY) (CIK 0001175680)

Letter

July 14, 2014 Via E -mail Nader Z. Pourhassan, Ph.D. President and Chief Executive Officer CytoDyn Inc . 1111 Main Street, Suite 660 Vancouver, Washington 98660

Re: CytoDyn Inc. Preliminary Proxy Statement on Schedule 14A Filed July 2, 2014 File No. 000 -49908

Dear Dr. Pourhassan :

We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Daniel Greenspan for

Show Raw Text
July 14, 2014

Via E -mail
Nader Z. Pourhassan, Ph.D.
President and Chief Executive Officer
CytoDyn Inc .
1111 Main Street, Suite 660
Vancouver, Washington 98660

Re: CytoDyn Inc.
 Preliminary Proxy Statement on Schedule 14A
Filed July 2, 2014
File No. 000 -49908

Dear Dr. Pourhassan :

We have completed our review of your filing .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the  Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Daniel Greenspan  for

Jeffrey P. Riedle r
Assistant Director